# A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

> **NCT02953535** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Magicbuvir
- **DRUG:** Sovaldi (fist dose)
- **DRUG:** Sovaldi (second dose)

## Key facts

- **NCT ID:** NCT02953535
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02953535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02953535, "A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02953535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*